Comparison of the Short-Term Effects of Intravitreal Triamcinolone Acetonide and Bevacizumab Injection for Diabetic Macular Edema.
10.3341/kjo.2011.25.3.156
- Author:
Ju Hwan SONG
1
;
Jung Joo LEE
;
Sang Joon LEE
Author Information
1. Department of Ophthalmology, Kosin University College of Medicine, Busan, Korea. hhiatus@hanmail.net
- Publication Type:Original Article ; Comparative Study ; Research Support, Non-U.S. Gov't
- Keywords:
Bevacizumab;
Diabetic retinopathy;
Intraocular pressure;
Macular edema;
Triamcinolone acetonide
- MeSH:
Aged;
Angiogenesis Inhibitors/*administration & dosage;
Antibodies, Monoclonal/*administration & dosage;
Diabetic Retinopathy/*drug therapy;
Female;
Glucocorticoids/*administration & dosage;
Humans;
Intravitreal Injections;
Macular Edema/*drug therapy;
Male;
Middle Aged;
Retrospective Studies;
Time Factors;
Treatment Outcome;
Triamcinolone Acetonide/*administration & dosage
- From:Korean Journal of Ophthalmology
2011;25(3):156-160
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To compare the short-term effects of intravitreal triamcinolone acetonide (IVTA) with those of intravitreal bevacizumab (IVB) injection for diabetic macular edema (DME). METHODS: The present retrospective, comparative case study included 58 eyes of 35 consecutive patients (IVTA group, 20 eyes; IVB group, 38 eyes) with DME. IVTA (4 mg) or IVB (1.25 mg) injection was performed under local anesthesia. The effects of injection for DME were evaluated using best-corrected visual acuity (BCVA), central macular thickness (CMT) by optical coherence tomography and intraocular pressure (IOP) by applanation tonometer. Patients underwent eye examinations, including BCVA, CMT, and IOP at pre-injection, 2, 4, and 8 weeks after injection. RESULTS: BCVA (logarithm of the minimum angle of resolution) +/- SD at pre-injection, 2, 4, and 8 weeks after injection was 0.67 +/- 0.40, 0.56 +/- 0.35 (p = 0.033), 0.55 +/- 0.33 (p = 0.041), and 0.43 +/- 0.31 (p = 0.001) in the IVTA group and 0.51 +/- 0.31, 0.42 +/- 0.26 (p = 0.003), 0.43 +/- 0.32 (p = 0.001), and 0.43 +/- 0.27 (p = 0.015) in the IVB group, respectively. CMT (microm) +/- SD at pre-injection, 2, 4, and 8 weeks after injection was 400.4 +/- 94.9, 332.8 +/- 47.4 (p = 0.002), 287.5 +/- 49.1 (p = 0.007), and 282.5 +/- 49.6 (p = 0.043) in the IVTA group and 372.6 +/- 99.5, 323.2 +/- 72.4 (p = 0.077), 360.9 +/- 50.3 (p = 0.668), 368.2 +/- 88.6 (p = 0.830) in the IVB group, respectively. CONCLUSIONS: The effects of IVTA for BCVA were more favorable than were those of IVB and were consistent throughout the eight weeks after injection. IVTA significantly reduced CMT during the eight weeks after injection, while IVB did not.
